MAPS PBC announces positive topline results from long-term observational follow-up study on MDMA-assisted therapy for treatment of PTSD.
Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session.
Findings are consistent with previously published Phase 2 data[1] on the sustained effect of MDMA-assisted therapy for the treatment of PTSD.
Read more
Here’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color
Read more
Check out this podcast— Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies Rick Doblin discusses the role of MDMA-guided psychotherapy in treating PTSD.
Rick shares the story of how he developed a passion for healing the brain with psychedelics and the 35-year journey he’s endured to build a growing non-profit organization. He also explains how to effectively work with drugs that have been aggressively stigmatized and politicized.
Read more